EP4719366A1 - Inhibiteurs de sortiline pour le traitement de patients atteints de tumeurs neuroendocrines fonctionnelles - Google Patents

Inhibiteurs de sortiline pour le traitement de patients atteints de tumeurs neuroendocrines fonctionnelles

Info

Publication number
EP4719366A1
EP4719366A1 EP24725852.8A EP24725852A EP4719366A1 EP 4719366 A1 EP4719366 A1 EP 4719366A1 EP 24725852 A EP24725852 A EP 24725852A EP 4719366 A1 EP4719366 A1 EP 4719366A1
Authority
EP
European Patent Office
Prior art keywords
sortilin
inhibitor
carbamoyl
benzoic acid
methylpyridin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24725852.8A
Other languages
German (de)
English (en)
Inventor
Michael SIGAL
Felix BOLDUAN
Bertram Wiedenmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP4719366A1 publication Critical patent/EP4719366A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention appartient au domaine des thérapies anticancéreuses, et concerne plus particulièrement des thérapies visant à améliorer la santé de patients souffrant de tumeurs neuroendocrines (NET) fonctionnelles ou de néoplasmes neuroendocriniens (NEN) fonctionnels. En particulier, l'invention divulgue l'utilisation d'inhibiteurs de sortiline pour traiter une affection associée à la libération d'un facteur endocrinien et/ou paracrine tel que la sérotonine par un néoplasme neuroendocrinien fonctionnel chez un sujet, par exemple le syndrome carcinoïde, une maladie cardiaque carcinoïde et/ou une crise carcinoïde. L'inhibiteur de sortiline peut être fourni dans une composition pharmaceutique et peut être un inhibiteur à petite molécule ayant une masse moléculaire inférieure ou égale à 800 daltons, un anticorps anti-sortiline, un acide nucléique inhibiteur, une chimère ciblant la protéolyse, un inhibiteur à base de peptide ou une combinaison de ceux-ci.
EP24725852.8A 2023-05-26 2024-05-10 Inhibiteurs de sortiline pour le traitement de patients atteints de tumeurs neuroendocrines fonctionnelles Pending EP4719366A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP23175836 2023-05-26
PCT/EP2024/062984 WO2024245719A1 (fr) 2023-05-26 2024-05-10 Inhibiteurs de sortiline pour le traitement de patients atteints de tumeurs neuroendocrines fonctionnelles

Publications (1)

Publication Number Publication Date
EP4719366A1 true EP4719366A1 (fr) 2026-04-08

Family

ID=86605642

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24725852.8A Pending EP4719366A1 (fr) 2023-05-26 2024-05-10 Inhibiteurs de sortiline pour le traitement de patients atteints de tumeurs neuroendocrines fonctionnelles

Country Status (2)

Country Link
EP (1) EP4719366A1 (fr)
WO (1) WO2024245719A1 (fr)

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101614558B1 (ko) 2008-04-27 2016-04-22 하. 룬드벡 아크티에셀스카브 인간 소르틸린의 결정 구조 및 소르틸린에 대한 리간드를 확인하기 위한 이의 용도
SI3280441T1 (sl) 2015-04-07 2022-01-31 Alector Llc Protitelesa anti-sortilin in metoda njihove uporabe
US10180422B1 (en) * 2017-08-22 2019-01-15 Scripps Health Methods of treating a neuroendocrine tumor
LT3618928T (lt) 2018-07-13 2023-04-11 Alector Llc Anti-sortilino antikūnai ir jų panaudojimo būdai
EP3881840A1 (fr) 2020-03-19 2021-09-22 Insusense ApS Antagonistes de sortilin à utiliser dans le traitement de la rétinopathie diabétique
EP4255930A1 (fr) 2020-12-02 2023-10-11 Alector LLC Méthodes d'utilisation d'anticorps anti-sortiline
EP4032891A1 (fr) 2021-01-20 2022-07-27 Insusense ApS Dérivés de pyridine comme modulateurs de l'activité de la sortiline
EP4079748A1 (fr) 2021-04-23 2022-10-26 Insusense ApS Modulateurs de la activité de sortiline
EP4089102A1 (fr) 2021-05-14 2022-11-16 Insusense ApS Modulateurs de la activité de sortiline
EP4144352A1 (fr) 2021-09-03 2023-03-08 Insusense ApS Dérivés de l'acide 2-amino-5,5-diméthylexanoïque en tant que modulateurs de sortiline destinés au traitement des maladies du système nerveux central
SE545408C2 (en) 2021-12-02 2023-09-05 Sortina Pharma Ab Sortilin inhibitors
EP4234014A1 (fr) 2022-02-28 2023-08-30 Insusense ApS Carbamates et/ou urées dérivés d'acides amninés pour le traitement de maladies liées à la sortiline
EP4342530A1 (fr) 2022-09-02 2024-03-27 Insusense ApS Modulateurs de la sortiline

Also Published As

Publication number Publication date
WO2024245719A1 (fr) 2024-12-05

Similar Documents

Publication Publication Date Title
US8007790B2 (en) Methods for treating polycystic kidney disease (PKD) or other cyst forming diseases
CN114144423B (zh) 使用与免疫检查点抑制剂组合递送的siRNA沉默TGF-BETA 1和COX2以治疗癌症
JP7536049B2 (ja) 血管新生障害の処置
EP4025590A1 (fr) Procédés et compositions pour le traitement du cancer
Umbarkar et al. Repurposing Nintedanib for pathological cardiac remodeling and dysfunction
JP2025011102A (ja) 肝疾患を治療するための組成物および方法
JP2021527651A (ja) Ｃ／ＥＢＰアルファｓａＲＮＡを含む併用療法
WO2012064967A2 (fr) Le récepteur activateur du ligand nf-kb, issu de cellules cancéreuses, entraîne des métastases des os et des tissus mous
US20130263297A1 (en) Methods of treating cancer
EP4719366A1 (fr) Inhibiteurs de sortiline pour le traitement de patients atteints de tumeurs neuroendocrines fonctionnelles
CN112353940B (zh) 一种用于预防或治疗抑郁症的药物及其应用
JP2026506642A (ja) 神経膠腫を治療する方法
CN112007157B (zh) Mrg15蛋白或基因作为靶点在代谢疾病治疗和预防中的应用
WO2021075559A1 (fr) Inhibiteur de croissance cellulaire ou inducteur de mort cellulaire pour fibroblastes associés au cancer
US20220193113A1 (en) Novel therapeutic agent for gastrointestinal cancer and method for screening for the same
US20160215289A1 (en) Methods of modulating lymphangiogenesis, e.g., to treat corneal transplant rejection, in a subject
JP2025521567A (ja) 胆汁うっ滞及び／又は胆汁うっ滞に関連する線維症の予防、進行の遅延又は治療のための方法
WO2024204685A1 (fr) Composition pharmaceutique pour le traitement et/ou la prévention du cancer
CN116173040A (zh) Xmd17109作为arih1激动剂的用途
JP2014105177A (ja) 糖尿病治療用医薬組成物及びその有効成分のスクリーニング方法
HK40023089A (en) Method for identifying nucleic acids regulating metastasation
HK1193429B (en) Treatment of angiogenesis disorders
HK1193429A (en) Treatment of angiogenesis disorders

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20251201

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR